NCT05141305View on ClinicalTrials.gov

Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

PHASE3CompletedINTERVENTIONAL
Enrollment

516

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

January 29, 2024

Study Completion Date

February 9, 2024

Conditions
Ischemic Stroke, Acute
Interventions
DRUG

tenecteplase (0.25 mg/kg, Max 25 mg)

tenecteplase (0.25 mg/kg) is being used.

DRUG

standard medical treatment

Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.

Trial Locations (1)

100000

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER